Clinical Trial Update: Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II clinical trial evaluating CD5 CAR-engineered IL-15-transduced cord blood-derived NK cells with lymphodepleting chemotherapy for relapsed or refractor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Drugs mentioned

• CD5 CAR-engineered IL-15-transduced cord blood-derived NK cells

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Hematological Malignancy | Phase 1, Phase 2 | Status: RECRUITING